William C. Roberts
Investor Relations Kontakt bei G1 THERAPEUTICS, INC.
Profil
William C.
Roberts is currently the VP-Investor Relations & Corporate Communications at G1 Therapeutics, Inc. Prior to this, he held positions as Vice President-Communications & Investor Relations at Shire ViroPharma, Inc., Vice President-Investor Relations & Communications at Zynerba Pharmaceuticals, Inc., Head-Investor Relations at Medimmune, Inc., Vice President-Investor Relations at Adaptimmune Therapeutics Plc, and Vice President-Corporate Communications at Viropharma, Inc. Mr. Roberts received his undergraduate degree from the University of Virginia and his MBA from Keller Graduate School of Management.
Aktive Positionen von William C. Roberts
| Unternehmen | Position | Beginn |
|---|---|---|
| G1 THERAPEUTICS, INC. | Investor Relations Kontakt | 04.01.2021 |
Ehemalige bekannte Positionen von William C. Roberts
| Unternehmen | Position | Ende |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Investor Relations Kontakt | 23.10.2017 |
| Viropharma, Inc. | Public Communications Contact | - |
| ZYNERBA PHARMACEUTICALS, INC. | Investor Relations Kontakt | - |
| Medimmune, Inc. | Investor Relations Kontakt | - |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Investor Relations Kontakt | - |
Ausbildung von William C. Roberts
| Keller Graduate School of Management | Masters Business Admin |
| University of Virginia | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| G1 THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
| Medimmune, Inc. | Health Technology |
| Viropharma, Inc. |
